Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies
- PMID: 29135051
- PMCID: PMC5728699
- DOI: 10.1111/aji.12785
Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies
Abstract
Problem: Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA). aPL recognizing beta2 glycoprotein I can target the uterine endothelium, however, little is known about its response to aPL. This study characterized the effect of aPL on human endometrial endothelial cells (HEECs), and the influence of LMWH and ASA.
Method of study: HEECs were exposed to aPL or control IgG, with or without low-dose LMWH and ASA, alone or in combination. Chemokine and angiogenic factor secretion were measured by ELISA. A tube formation assay was used to measure angiogenesis.
Results: aPL increased HEEC secretion of pro-angiogenic VEGF and PlGF; increased anti-angiogenic sFlt-1; inhibited basal secretion of the chemokines MCP-1, G-CSF, and GRO-α; and impaired angiogenesis. LMWH and ASA, alone and in combination, exacerbated the aPL-induced changes in the HEEC angiogenic factor and chemokine profile. There was no reversal of the aPL inhibition of HEEC angiogenesis by either single or combination therapy.
Conclusion: By aPL inhibiting HEEC chemokine secretion and promoting sFlt-1 release, the uterine endothelium may contribute to impaired placentation and vascular transformation. LMWH and ASA may further contribute to endothelium dysfunction in women with obstetric APS.
Keywords: angiogenic; antiphospholipid antibody; chemokine; endothelium; pregnancy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Figures






Similar articles
-
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2. Cochrane Database Syst Rev. 2020. PMID: 32358837 Free PMC article.
-
Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin.Am J Reprod Immunol. 2011 Oct;66(4):286-96. doi: 10.1111/j.1600-0897.2011.01007.x. Epub 2011 May 4. Am J Reprod Immunol. 2011. PMID: 21545366
-
Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis.PLoS One. 2012;7(1):e29660. doi: 10.1371/journal.pone.0029660. Epub 2012 Jan 3. PLoS One. 2012. PMID: 22235321 Free PMC article.
-
Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function.Obstet Gynecol. 2011 Nov;118(5):1021-1028. doi: 10.1097/AOG.0b013e31823234ad. Obstet Gynecol. 2011. PMID: 22015869 Free PMC article.
-
Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature.Ann N Y Acad Sci. 2007 Jun;1108:505-14. doi: 10.1196/annals.1422.054. Ann N Y Acad Sci. 2007. PMID: 17894016 Review.
Cited by
-
Progesterone: The Key Factor of the Beginning of Life.Int J Mol Sci. 2022 Nov 16;23(22):14138. doi: 10.3390/ijms232214138. Int J Mol Sci. 2022. PMID: 36430614 Free PMC article. Review.
-
Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study.J Int Med Res. 2024 Jan;52(1):3000605231225349. doi: 10.1177/03000605231225349. J Int Med Res. 2024. PMID: 38263912 Free PMC article.
-
Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome.Front Physiol. 2021 Dec 2;12:764702. doi: 10.3389/fphys.2021.764702. eCollection 2021. Front Physiol. 2021. PMID: 34925061 Free PMC article.
-
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2. Cochrane Database Syst Rev. 2020. PMID: 32358837 Free PMC article.
-
Immunological Risk Factors in Recurrent Pregnancy Loss in Patients With Hereditary Thrombophilia.Cureus. 2024 Mar 20;16(3):e56555. doi: 10.7759/cureus.56555. eCollection 2024 Mar. Cureus. 2024. PMID: 38533322 Free PMC article.
References
-
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG DEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4:295–306. - PubMed
-
- Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013;65:1869–1873. - PubMed
-
- Chamley LW, Allen JL, Johnson PM. Synthesis of beta2 glycoprotein 1 by the human placenta. Placenta. 1997;18:403–410. - PubMed
-
- Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, Bulla R, Grossi C, Borghi MO, Meroni P, Tedesco F. In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118:4231–4238. - PubMed
-
- Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B, Borghi MO. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012;21:708–710. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous